ArticleMacromolecular bioscience2019
Molecular Imprinting of Cyclodextrin Supramolecular Hydrogels Improves Drug Loading and Delivery.
Article in Macromolecular bioscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cyclodextrins as eminent constituents in nanoarchitectonics for drug delivery systems.Beilstein journal of nanotechnology · 2023Review
- Ultrasound Triggered Drug Release from Affinity-Based β-Cyclodextrin Polymers for Infection Control.Annals of biomedical engineering · 2021Article
- Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting.Journal of pharmaceutical sciences · 2021Article
- Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety.Polymers · 2020Article
- Resveratrol Delivery from Implanted Cyclodextrin Polymers Provides Sustained Antioxidant Effect on Implanted Neural Probes.International journal of molecular sciences · 2020Article
- Commercial hydrogels for biomedical applications.Heliyon · 2020Review
- Affinity Effects on the Release of Non-Conventional Antifibrotics from Polymer Depots.Pharmaceutics · 2020Article
- Article
- Serum biomolecules unable to compete with drug refilling into cyclodextrin polymers regardless of the form.Journal of materials chemistry. B · 2019Article
- Cyclodextrin Polymer Preserves Sirolimus Activity and Local Persistence for Antifibrotic Delivery over the Time Course of Wound Healing.Molecular pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cyclodextrin-based controlled delivery materials have previously been developed for controlled release of different therapeutic drugs. In this study, a supramolecular hydrogel made from cyclodextrin-based macromonomers is subjected to molecular imprinting to investigate the impact on release kinetics and drug loading, when compared with non-imprinted, or alternately imprinted hydrogels. Mild synthesis conditions are used to molecularly imprint three antibiotics-novobiocin, rifampicin, and vancomycin-and to test two different hydrogel chemistries. The release profile and drug loading of the molecularly imprinted hydrogels are characterized using ultraviolet spectroscopy over a period of 35 days and compared to non-imprinted, and alternately imprinted hydrogels. While only modest differences are observed in the release rate of the antibiotics tested, a substantial difference is observed in the total drug-loading amount possible for hydrogels releasing drugs which has been templated by those drugs. Hydrogels releasing drugs which are templated by other drugs do not show improved release or loading. Analysis by FTIR does not show substantial incorporation of drug into the polymer. Lastly, bioactivity assays confirmed long-term stability and release of incorporated antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.